First-Line Treatment for Urticaria in Children

Initial Treatment Approach

The American Academy of Pediatrics recommends second-generation non-sedating H1 antihistamines as the first-line treatment for urticaria in children, with cetirizine, loratadine, desloratadine, fexofenadine, or levocetirizine as preferred options 1, 2
Begin with a second-generation antihistamine at standard dosing, and offer the child's family a choice between at least two different antihistamines, as individual response and tolerance vary significantly between patients 1, 3, 2
Cetirizine has the shortest time to maximum concentration, making it advantageous when rapid symptom relief is needed 1, 3

If symptom control is inadequate after 2-4 weeks of standard dosing, increase the antihistamine dose up to 4 times the standard dose before adding other therapies 1, 3, 2
A four-fold dose of cetirizine was necessary to significantly improve multiple urticaria parameters in one study, though doubling the dose improved only pruritus 4

Oral corticosteroids can shorten the duration of acute urticaria episodes, and should be restricted to short courses of 3-10 days only for severe acute exacerbations or angioedema involving the mouth 1, 2
Long-term oral corticosteroids should not be used in chronic urticaria except in highly selected cases under specialist supervision 1

Identify and minimize aggravating factors including overheating, stress, alcohol, and certain medications, and control environmental temperature to decrease symptoms and reduce the need for antihistamines 1, 2
Avoid NSAIDs in aspirin-sensitive patients with urticaria 2
Cooling lotions can provide additional symptomatic relief 1

For chronic spontaneous urticaria unresponsive to high-dose antihistamines, consider omalizumab at 300 mg subcutaneously every 4 weeks, and allow up to 6 months to evaluate response before considering alternative treatments 1, 3, 2
Cyclosporine at 4 mg/kg per day for a maximum of 2 months is recommended for patients who fail both high-dose antihistamines and omalizumab, and is effective in approximately two-thirds of patients with severe autoimmune urticaria 1, 2

Intramuscular epinephrine is life-saving in anaphylaxis and severe laryngeal angioedema, with dosing weight-dependent: auto-injector pens deliver 300 µg for adults/adolescents or 150 µg for children weighing 15-30 kg 1

Approximately 50% of children with chronic urticaria presenting with wheals alone will be symptom-free within 6 months, while patients with both wheals and angioedema have a poorer prognosis, with over 50% still having active disease after 5 years 1, 2